Immunome, Inc. (IMNM) vs First Tracks Biotherapeutics, Inc. (TRAX)

Immunome, Inc. and First Tracks Biotherapeutics, Inc. are both Biotechnology companies. Immunome, Inc. and First Tracks Biotherapeutics, Inc. are of similar size ($2.2B and $2.2B). Across the 6 metrics below, First Tracks Biotherapeutics, Inc. leads on 4 and Immunome, Inc. on 2.

Valuation

Metric IMNM TRAX Biotechnology median
P/E n/m n/m 11.58
P/S 172.39 n/m 9.61
P/B 4.78 11.90 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 135.77 n/m 9.43
Earnings yield (13.79%) (10.29%) (32.28%)
Free cash flow yield (11.00%) (6.25%) (22.27%)

Profitability

Metric IMNM TRAX Biotechnology median
Gross margin 100.00% — 68.81%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (78.71%) 0.00% (50.30%)
Return on assets (70.23%) 0.00% (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMNM TRAX Biotechnology median
Revenue growth (TTM) 16.74% — 6.78%
EPS growth (last fiscal year) 51.40% — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IMNM TRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.66 9.16 4.74
Net debt to EBITDA 2.92 — 1.01

Dividend

Metric IMNM TRAX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric IMNM TRAX Biotechnology median
Market cap 2.20b 2.20b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack